Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Recce Pharmaceuticals Ltd. ( (AU:RCE) ).
Recce Pharmaceuticals Ltd announced its participation in the 2025 Military Health System Research Symposium, where it will present findings on its synthetic anti-infective, RECCE® 327. The research highlights the compound’s efficacy against multiple bioterrorism pathogens, including Anthrax and Plague, showcasing its potential as a novel countermeasure in biodefense. This development is part of a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases, underscoring the importance of innovative solutions in military and public health strategies.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company in the pharmaceutical industry, focusing on the development of synthetic anti-infectives. Their primary product, RECCE® 327, is designed to combat high-priority bioterrorism pathogens and address emerging infectious disease threats.
Average Trading Volume: 156,518
Technical Sentiment Signal: Sell
Current Market Cap: A$108.4M
See more insights into RCE stock on TipRanks’ Stock Analysis page.